Pravastatin - CAS 81093-37-0
Catalog number: 81093-37-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C23H36O7
Molecular Weight:
424.53
COA:
Inquire
Targets:
HMG-CoA Reductase (HMGCR)
Description:
Pravastatin is an antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase with IC50 of 5.6 μM. It is used in combination with diet, exercise, and weight loss for lowering cholesterol and preventing cardiovascular disease. It is a synthetic lipid-lowering agent. It lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing major histocompatibility complex II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. It is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is used to reduce LDL cholesterol and triglyceride levels and increase HDL cholesterol in the prevention of cardiovascular disease.
Purity:
98%
Appearance:
White to yellowish white powder or crystalline powder
Synonyms:
1-Naphthaleneheptanoicacid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-,[1S-[1a(bS*,dS*),2a,6a,8b(R*),8aa]]-;3b-Hydroxycompactin;Eptastatin;Mevalothin;Pravastatin acid;Pravachol; Pravastatina;Pravastatine;Pravastatinum;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
Solubility:
10 mM in H2O (free soluble)
Storage:
2-8°C
MSDS:
Inquire
Application:
Pravastatin acts as a competitive inhibitor of HMG CoA reductase. It is a synthetic lipid-lowering agent. It is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease. It is used to reduce LDL cholesterol and triglyceride levels and increase HDL cholesterol in the prevention of cardiovascular disease.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Grams to Kilograms
Boiling Point:
634.5±55.0 °C | Condition: Press: 760 Torr
Melting Point:
171.2-173 °C
Density:
1.21±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
TUZYXOIXSAXUGO-PZAWKZKUSA-N
InChI:
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
Canonical SMILES:
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
1.Efficacy of Statin Therapy in Inducing Coronary Plaque Regression in Patients with Low Baseline Cholesterol Levels.
Wakabayashi K1, Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Miyake S, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Suzuki H, Michishita I; TRUTH investigators. J Atheroscler Thromb. 2016 Mar 31. [Epub ahead of print]
AIM: The efficacy of statin therapy in inducing coronary plaque regression may depend on baseline cholesterol levels. We aimed to determine the efficacy of statin therapy in inducing coronary plaque regression in statin-naïve patients with low cholesterol levels using serial intravascular ultrasound (IVUS) data from the treatment with statin on atheroma regression evaluated by virtual histology IVUS (TRUTH) study.
2.The role of acid-base imbalance in statin-induced myotoxicity.
Taha DA1, De Moor CH2, Barrett DA2, Lee JB1, Gandhi RD2, Hoo CW1, Gershkovich P3. Transl Res. 2016 Mar 29. pii: S1931-5244(16)00107-9. doi: 10.1016/j.trsl.2016.03.015. [Epub ahead of print]
Disturbances in acid-base balance, such as acidosis and alkalosis, have potential to alter the pharmacologic and toxicologic outcomes of statin therapy. Statins are commonly prescribed for elderly patients who have multiple comorbidities such as diabetes mellitus, cardiovascular, and renal diseases. These patients are at risk of developing acid-base imbalance. In the present study, the effect of disturbances in acid-base balance on the interconversion of simvastatin and pravastatin between lactone and hydroxy acid forms have been investigated in physiological buffers, human plasma, and cell culture medium over pH ranging from 6.8-7.8. The effects of such interconversion on cellular uptake and myotoxicity of statins were assessed in vitro using C2C12 skeletal muscle cells under conditions relevant to acidosis, alkalosis, and physiological pH. Results indicate that the conversion of the lactone forms of simvastatin and pravastatin to the corresponding hydroxy acid is strongly pH dependent.
3.Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: 16 Years of Follow-Up of the LIPID Study.
Hague WE1, Simes J2, Kirby A2, Keech AC2, White HD3, Hunt D4, Nestel PJ5, Colquhoun DM6, Pater H2, Stewart RA3, Sullivan DR7, Thompson PL8, West M9, Glasziou PP10, Tonkin AM11; LIPID investigators. Circulation. 2016 Mar 25. pii: CIRCULATIONAHA.115.018580. [Epub ahead of print]
BACKGROUND: -We aimed to assess the long-term effects of treatment with statin therapy on all-cause mortality, cause-specific mortality, and cancer incidence from extended follow-up of the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial.
4.Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment.
Cheng Y1, Freeden C1, Zhang Y1, Abraham P1, Shen H1, Wescott D1, Humphreys WG1, Gan J1, Lai Y1. Biopharm Drug Dispos. 2016 Apr 5. doi: 10.1002/bdd.2011. [Epub ahead of print]
The bile salt export pump (BSEP) is expressed on the canalicular membrane of hepatocytes regulating liver bile salt excretion, and impairment of BSEP function may lead to cholestasis in humans. Herein, we explored drug biliary excretion, as well as serum chemistry, individual bile acid concentrations and liver transporter expressions, in SAGE Bsep knockout (KO) rat model. It was observed that the Bsep protein in KO rats was decreased to 15% of that in wild type (WT), as quantified using LC-MS/MS. While the levels of Ntcp and Mrp2 were not significantly altered, Mrp3 expression increased and Oatp1a1 decreased in KO animals. Compared with WT rats, KO rats had similar serum chemistry and showed normal liver transaminases. Although the total plasma bile salts and bile flow were not significantly changed in Bsep KO rats, individual bile acids in plasma and liver did demonstrate variable changes, indicating the impact of Bsep KO. Following an intravenous dose of deuterium labeled taurocholic acid (D4-TCA, 2 mg/kg), D4-TCA plasma exposure was higher and bile excretion was delayed approximately 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related HMG-CoA Reductase (HMGCR) Products


CAS 503-49-1 Meglutol

Meglutol
(CAS: 503-49-1)

Meglutol is a hypolipidemic agent which inhibits the activity of hydroxymethylglutarryl CoA reductases.

CAS 147526-32-7 Pitavastatin Calcium

Pitavastatin Calcium
(CAS: 147526-32-7)

Pitavastatin calcium is a novel member of the medication class of statins.

CAS 126411-39-0 SR 12813

SR 12813
(CAS: 126411-39-0)

SR 12813 is a pregnane X receptor (PXR) agonist (EC50 = 200 and 700 nM for human and rabbit PXR, respectively) that activates the farnesoid X receptor (FXR) at ...

CAS 147098-20-2 Rosuvastatin Calcium

Rosuvastatin Calcium
(CAS: 147098-20-2)

Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.

CAS 81093-37-0 Pravastatin

Pravastatin
(CAS: 81093-37-0)

Pravastatin is an antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase with IC...

CAS 73573-88-3 Mevastatin

Mevastatin
(CAS: 73573-88-3)

Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself.

CAS 93957-54-1 Fluvastatin

Fluvastatin
(CAS: 93957-54-1)

Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR) with IC50 of 8 nM. It belongs to a class of the statin drug and is ...

CAS 134523-00-5 Atorvastatin

Atorvastatin
(CAS: 134523-00-5)

Atorvastatin, a HMG-CoA reductase inhibitor, could be used to reduce cholesterol and prevent cardiovascular related disease.

Chemical Structure

CAS 81093-37-0 Pravastatin

Quick Inquiry

Verification code

Featured Items